<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771156</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-21-0044</org_study_id>
    <nct_id>NCT04771156</nct_id>
  </id_info>
  <brief_title>Ketorolac in Palatoplasty</brief_title>
  <official_title>Ketorolac in Palatoplasty: A Randomized Blinded Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if the addition of IV Ketorolac to usual care multi-modal&#xD;
      pain therapy compared to usual care will improve oral intake post-operatively&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of oral intake</measure>
    <time_frame>from arrival to Post-Anesthesia Care Unit (PACU) to 24 hours post surgery</time_frame>
    <description>This will be measured in mL's of fluids</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by the Faces, Legs, Activity, Cry, Consolability (FLACC) scale</measure>
    <time_frame>immediately upon arrival at PACU</time_frame>
    <description>This scale has 5 questions and each is scored from 0-2,higher number indicating a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by the Faces, Legs, Activity, Cry, Consolability (FLACC) scale</measure>
    <time_frame>24 hours post surgery</time_frame>
    <description>This scale has 5 questions and each is scored from 0-2,higher number indicating a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by the Faces, Legs, Activity, Cry, Consolability (FLACC) scale</measure>
    <time_frame>48 hours post surgery</time_frame>
    <description>This scale has 5 questions and each is scored from 0-2,higher number indicating a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first oral intake</measure>
    <time_frame>within 24 hours post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Post-operative bleeding that requires either transfusion or Unplanned return to Operating Room</measure>
    <time_frame>24 hours and 48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Post-operative narcotic usage (recorded in Morphine milligram Equivalents)</measure>
    <time_frame>from arrival to PACU to discharge(24-48 hours post surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who need narcotic prescription at discharge</measure>
    <time_frame>at discharge(24-48 hours post surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function measured in mL/kg of urine output</measure>
    <time_frame>from arrival to PACU to discharge (24-48 hours post surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with post operative complications</measure>
    <time_frame>from arrival to PACU to discharge (24-48 hours post surgery)</time_frame>
    <description>post operative complications include,Unplanned return to OR, ER or unplanned clinic visit , Infection, Fever</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Cleft Lip and Palate</condition>
  <arm_group>
    <arm_group_label>Experimental group (Ketorolac)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac</description>
    <arm_group_label>Experimental group (Ketorolac)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Patient with Cleft palate (Complete and incomplete), with or without cleft lip, unilateral&#xD;
        or bilateral&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Syndromic Cleft Palate patients&#xD;
&#xD;
          -  Previous palatoplasty&#xD;
&#xD;
          -  Major unrepaired cardiac malformation&#xD;
&#xD;
          -  History of GI complications (GI Bleed, Gastric Ulceration)&#xD;
&#xD;
          -  History of Renal disorder&#xD;
&#xD;
          -  History of coagulopathy (As contraindication to NSAID use)&#xD;
&#xD;
          -  Feeding tube dependency&#xD;
&#xD;
          -  Patients whose parents refuse to consent to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew R Grieves, MD,MS,FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew R Greives, MD,MS,FACS</last_name>
    <phone>(713) 500-7275</phone>
    <email>Matthew.R.Greives@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alfredo Cepeda Jr., MD</last_name>
    <phone>(713) 500-7216</phone>
    <email>Alfredo.Cepeda@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew R Greives, MD,MS,FACS</last_name>
      <phone>713-500-7275</phone>
      <email>Matthew.R.Greives@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alfredo Cepeda Jr., MD</last_name>
      <phone>(713) 500-7216</phone>
      <email>Alfredo.Cepeda@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Matthew Greives</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cleft Lip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

